Will Absci use AMD GPUs for over 50% of its AI chips by mid-2025?
Yes • 50%
No • 50%
Official statements from Absci or AMD, or credible reports from major tech news outlets
AMD Invests $20 Million in Absci via PIPE to Enhance AI Drug Discovery with AMD GPUs
Jan 8, 2025, 01:19 PM
Advanced Micro Devices Inc. (AMD) has announced a strategic investment of $20 million in Absci Corporation (ABSI), a company focused on AI-driven drug discovery. The investment, structured as a private investment in public equity (PIPE), aims to enhance AMD's presence in the healthcare sector by leveraging its artificial intelligence chips. This collaboration will see Absci deploying AMD's high-performance compute and software solutions to advance the development of next-generation antibody therapeutics. The partnership is part of AMD's broader strategy to expand into life sciences and other industries, positioning its graphics processing units (GPUs) for specialized applications. Absci, based in Washington state, currently utilizes over 470 AI chips, predominantly from Nvidia, but plans to increase its use of AMD's GPUs following this investment.
View original story
Minimal adoption • 25%
Not adopted • 25%
Partially adopted in some pipelines • 25%
Fully adopted across all pipelines • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
Oracle • 25%
Microsoft • 25%
Meta • 25%
TensorWave • 25%
Meta • 25%
Amazon • 25%
Google • 25%
Microsoft • 25%
500,000 to 750,000 • 25%
Less than 500,000 • 25%
More than 1,000,000 • 25%
750,001 to 1,000,000 • 25%
Other • 25%
Tesla Inc. • 25%
Microsoft • 25%
Meta Platforms Inc. • 25%
Four • 25%
Five • 25%
Three • 25%
More than five • 25%
Stock price changes by less than 10% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by more than 20% • 25%
Stock price decreases • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
No new partnerships • 25%
More than 3 new partnerships • 25%
2 to 3 new partnerships • 25%
1 new partnership • 25%